Sichuan Kelun Pharmaceutical (SHE:002422), through its subsidiaries, granted Switzerland-based Windward Bio the right to commercialize a anti-thymic stromal lymphopoietin worldwide, according to a Monday filing with the Shenzhen Stock Exchange.
The anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb) SKB378/HBM93781, which is intended to treat pulmonary diseases, was developed by Harbour Biopharmaceuticals Holdings, one of the pharmaceutical company's subsidiaries that signed the commercial deal with Sichuan Kelun Botai Biopharmaceutical.
Harbour Biopharma, which is also the drug's licensor, is eligible to receive upfront and milestone payments of up to $970 million, as well as tiered royalties ranging from single-digit to double-digit percentages based on net sales. The upfront and near-term payments amount to $45 million, including cash consideration and equity in Windward Bio's parent company, the filing added.
Harbour Biopharma is also eligible to receive additional payments if Windward Bio undergoes a change in company control or enters into a sublicense agreement with a third party.
The agreement came after Windward Bio raised $200 million from its latest Series A fundraising round led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。